Eliquis® (apixaban) demonstrated comparable efficacy and significantly lower rates of major bleeding in patients compared to current standard of care for the treatment of acute venous thromboembolism
PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of ...
